ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1211

ANTI-Cyclic Citrullinated Protein Antibodies Induce Inflammation and Oxidative Stress in WHITE Blood CELLS of Rheumatoid Arthritis Patients

Chary Lopez-Pedrera1, Carlos Perez-Sanchez1, Patricia Ruiz-Limon1, Mª Angeles Aguirre2, Rosario M. Carretero-Prieto1, Antonio Rodriguez-Ariza3, Nuria Barbarroja1, Pilar Font1, Francisco Martinez2, Inmaculada Gomez-Gracia2, Mª Jose Cuadrado4 and Eduardo Collantes-Estevez2, 1Rheumatology Unit, IMIBIC-Reina Sofia University Hospital, Cordoba, Spain, 2Rheumatology, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, 3Oncology Service and Research Unit, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, 4Lupus Research Unit, The Rayne Institute, London, United Kingdom

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: anti-CCP antibodies, Atherosclerosis, Cardiovascular disease and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumamtoid Arthritis - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Anti-cyclic citrulinated protein antibodies (anti-CCP) are the most specific autoantibody markers in rheumatoid arthritis (RA) patients. However no previous studies have evaluated their role in the atherogenic process and cardiovascular (CV) risk in RA. The aim of this study was to investigate the role of anti-CCP antibodies in the induction of a pro-oxidative and inflammatory status in white blood cells, and their relationship with chronic inflammation and early atherogenesis in RA.

Methods:

Fifty three RA patients and 31 healthy donors were included. Tissue factor (TF), protease activated receptors (PARs) expression, peroxides and peroxinitrites levels, and mitochondrial membrane potential (MMP), were analyzed by flow cytometry in white blood cells; glutathione peroxidase activity (GPx) was evaluated in cell lysates. Atherosclerosis/CV risk markers were also evaluated. RT-PCR was performed to elucidate the cellular origin of plasma inflammatory molecules. The carotid-intimate media thickness (CIMT) was measured as a surrogate marker of atherosclerosis. In parallel in vitro studies, isolated monocytes, lymphocytes, or neutrophils were incubated with non-specific human IgG or with purified anti-CCP antibodies.

Results:

Increased expression of TF and PAR2 was found in neutrophils from RA patients, with higher plasma levels of VEGF, tPA, MCP1, MIP1α, TNFα , IL-2, -6, -8, -17A and -23. RA monocytes and neutrophils had higher peroxides and peroxynitrite levels, more depolarised mitochondria and lower GPx activity. Significantly higher levels of mRNA MCP-1, IL-1ß, -6, -8, and TF were found in monocytes, pointing to the main cell sources of inflammatory molecules in RA. Notably, augmented titres of anti-CCPs were not only directly related to increased expression of protrombotic, pro-inflammatory and oxidative stress markers, but also to increased CIMT. Moreover, in vitro treatment of with anti-CCP increased peroxide production in monocytes and neutrophils, as well as on the percentage of cells with increased MMP. Anti-CCP treatment in monocytes induced elevated cell surface TF expression and increased mRNA levels of MCP-1, IL-1ß, -6, and -8 while in lymphocytes provoked increased IL-1ß, -2, -6, -8, TNFα, and VEGF mRNA expression levels. No changes in cytokine mRNAs were found in neutrophils.

Conclusion:

1) Anti-CCP antibodies directly induce inflammation and oxidative stress in RA patients. 2) Monocytes and lymphocytes are key mediators of the anti-CCP-induced inflammatory state by expressing particular cytokines, which may constitute promising therapeutical targets for the prevention of atherosclerosis and CVD in RA patients. Support: JA0246/2009, P08-CVI-04234, PS09/01809, Spanish Foundation of Rheumatology.


Disclosure:

C. Lopez-Pedrera,
None;

C. Perez-Sanchez,
None;

P. Ruiz-Limon,
None;

M. A. Aguirre,
None;

R. M. Carretero-Prieto,
None;

A. Rodriguez-Ariza,
None;

N. Barbarroja,
None;

P. Font,
None;

F. Martinez,
None;

I. Gomez-Gracia,
None;

M. J. Cuadrado,
None;

E. Collantes-Estevez,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-cyclic-citrullinated-protein-antibodies-induce-inflammation-and-oxidative-stress-in-white-blood-cells-of-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology